Incannex Healthcare has been granted a pre-investigational new drug (IND) meeting with the US Food and Drug Administration (FDA) regarding progressing the company’s hydroxychloroquine/CBD drug cocktail IHL-675A in preventing acute respiratory distress syndrome (ARDS) and sepsis associated acute respiratory distress syndrome (SAARDS).
ARDS is a life-threatening injury characterised by fluid leakage on the lungs while SAARDS is often a deadly side effect of Covid-19.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
